NO20061925L - Farmasoytiske preparater for forebyggelse av overdose eller misbruk - Google Patents
Farmasoytiske preparater for forebyggelse av overdose eller misbrukInfo
- Publication number
- NO20061925L NO20061925L NO20061925A NO20061925A NO20061925L NO 20061925 L NO20061925 L NO 20061925L NO 20061925 A NO20061925 A NO 20061925A NO 20061925 A NO20061925 A NO 20061925A NO 20061925 L NO20061925 L NO 20061925L
- Authority
- NO
- Norway
- Prior art keywords
- overdose
- abuse
- prevention
- pharmaceutical preparations
- active agent
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003636 chemical group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50701203P | 2003-09-30 | 2003-09-30 | |
| US56801104P | 2004-05-05 | 2004-05-05 | |
| US56780004P | 2004-05-05 | 2004-05-05 | |
| US56780204P | 2004-05-05 | 2004-05-05 | |
| PCT/US2004/032131 WO2005032474A2 (en) | 2003-09-30 | 2004-09-30 | Pharmaceutical compositions for prevention of overdose or abuse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20061925L true NO20061925L (no) | 2006-06-29 |
Family
ID=34427058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061925A NO20061925L (no) | 2003-09-30 | 2006-04-28 | Farmasoytiske preparater for forebyggelse av overdose eller misbruk |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7375083B2 (pt) |
| EP (1) | EP1675555A4 (pt) |
| JP (1) | JP4691500B2 (pt) |
| KR (1) | KR100915284B1 (pt) |
| AU (2) | AU2004277400B2 (pt) |
| BR (1) | BRPI0414876A (pt) |
| CA (1) | CA2540678C (pt) |
| EA (1) | EA008864B1 (pt) |
| IL (1) | IL174683A0 (pt) |
| MX (1) | MXPA06003619A (pt) |
| NO (1) | NO20061925L (pt) |
| NZ (1) | NZ546226A (pt) |
| SG (1) | SG147485A1 (pt) |
| WO (1) | WO2005032474A2 (pt) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US20070060500A1 (en) * | 2000-08-22 | 2007-03-15 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
| US8394813B2 (en) * | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
| US20060014697A1 (en) | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| US7375082B2 (en) * | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
| US20070066537A1 (en) * | 2002-02-22 | 2007-03-22 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US20050065205A1 (en) | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US20040156844A1 (en) * | 2002-05-22 | 2004-08-12 | Curtis Wright | Tamper resistant oral dosage form |
| US8133881B2 (en) * | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
| SI1644019T2 (en) * | 2003-05-29 | 2018-04-30 | Shire Llc | Abuse resistant amphetamine compounds |
| US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| EA008864B1 (ru) | 2003-09-30 | 2007-08-31 | Нью Ривер Фармасьютикалз Инк. | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств |
| TW201206425A (en) * | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| BRPI0612440A2 (pt) * | 2005-04-08 | 2010-11-23 | New River Pharmaceuticals Inc | composição farmacêutica e uso de um profármaco de anfetamina |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| WO2007100668A2 (en) | 2006-02-24 | 2007-09-07 | Shire Llc | Antidepressant prodrugs |
| JP5457830B2 (ja) | 2006-04-03 | 2014-04-02 | オディディ，イサ | オルガノゾル被膜を含む制御放出送達デバイス |
| EP2007389A2 (en) * | 2006-04-14 | 2008-12-31 | Shire LLC | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
| US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| MX2008014794A (es) * | 2006-05-26 | 2009-04-08 | Pharmacofore Inc | Liberacion controlada de opioides fenolicos. |
| WO2008010223A2 (en) | 2006-07-17 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders |
| EP3332797A3 (en) | 2007-02-09 | 2018-08-01 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury |
| CA2678806C (en) * | 2007-02-21 | 2017-05-16 | Connected Health Systems, Llc | Treating adhd and other diseases involving inflammation |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CA2731801C (en) * | 2007-07-23 | 2013-11-26 | Kingsway Pharmaceuticals Inc. | Therapeutic formulations for the treatment of cold and flu-like symptoms |
| AU2008286914B2 (en) * | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| US20090192095A1 (en) * | 2008-01-18 | 2009-07-30 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
| US8207369B2 (en) | 2008-02-11 | 2012-06-26 | Ramot At Tel-Aviv University Ltd. | Conjugates for treating neurodegenerative diseases and disorders |
| WO2009149278A1 (en) * | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US20100221329A1 (en) | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US10849981B2 (en) | 2009-07-02 | 2020-12-01 | KemPham, Inc. | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
| UA102916C2 (uk) | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань |
| US8871780B2 (en) | 2009-07-02 | 2014-10-28 | Kempharm, Inc. | Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof |
| WO2011007247A1 (en) | 2009-07-17 | 2011-01-20 | Llc Shire | Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
| CN102695545B (zh) | 2009-09-08 | 2016-08-17 | 特色疗法股份有限公司 | 包括酶可剪切的酮改性的阿片样物质药物前体以及其可任选的抑制剂的组合物 |
| EP2509603A1 (en) | 2009-12-09 | 2012-10-17 | Biolinerx Ltd. | Methods of improving cognitive functions |
| US8715699B2 (en) | 2009-12-31 | 2014-05-06 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| US9125867B2 (en) * | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
| US20130059914A1 (en) | 2010-04-21 | 2013-03-07 | Signature Therapeutics, Inc. | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| WO2012037380A2 (en) | 2010-09-15 | 2012-03-22 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2012038963A1 (en) | 2010-09-22 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same |
| AU2012205733B2 (en) | 2011-01-11 | 2015-10-08 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
| JP6148182B2 (ja) | 2011-03-09 | 2017-06-14 | シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. | 複素環式リンカーを有する活性薬剤プロドラッグ |
| SG11201401856VA (en) | 2011-10-26 | 2014-05-29 | Kempharm Inc | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof |
| US20140275149A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| RU2683317C2 (ru) | 2014-11-25 | 2019-03-28 | Кемфарм, Инк. | Конъюгаты оксикодона с бензойной кислотой, производными бензойной кислоты и гетероарилкарбоновой кислотой |
| RU2683274C2 (ru) | 2014-12-02 | 2019-03-27 | Кемфарм, Инк. | Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты и оксиморфона, их пролекарства, способы получения и применение |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| US10449190B2 (en) | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
| US9987269B2 (en) | 2015-04-27 | 2018-06-05 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof |
| US10017519B2 (en) | 2015-04-27 | 2018-07-10 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
| US10226456B2 (en) | 2015-04-27 | 2019-03-12 | 3St Research Llc | Methods and compositions for preventing opioid abuse |
| WO2017098533A2 (en) * | 2015-12-11 | 2017-06-15 | Sun Pharmaceutical Industries Limited | Process for preparation of lisdexamphetamine |
| US12589083B2 (en) | 2019-05-07 | 2026-03-31 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| CN110200947A (zh) * | 2019-06-27 | 2019-09-06 | 深圳市泛谷药业股份有限公司 | 一种安非他酮肠溶缓释微丸胶囊及其制备方法 |
| CA3199184A1 (en) | 2020-11-18 | 2022-05-27 | Felix Lustenberger | Mdma prodrugs to assist psychotherapy |
| IL305493A (en) | 2021-03-09 | 2023-10-01 | Ensysce Biosciences Inc | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof |
| CA3230025A1 (en) | 2021-09-29 | 2023-04-06 | Lynn Kirkpatrick | Enzyme-cleavable methadone prodrugs and methods of use thereof |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1493824A1 (de) | 1964-01-27 | 1969-05-22 | Hoffmann La Roche | Verfahren zur Herstellung von Aminocarbonsaeureamiden |
| CH406567A (de) | 1964-02-10 | 1966-01-31 | Inventio Ag | Einrichtung zur Steuerung der Sollwertgrösse während des Verzögerungsvorganges bei Aufzügen mit drehzahlgeregeltem Antrieb |
| AU414154B2 (en) | 1965-02-03 | 1971-06-16 | fuji SHISHIN FILM KABUSHIKI KAISHA | Direct positive photographic materials |
| GB1112347A (en) | 1965-08-20 | 1968-05-01 | Pierre Wirth | Salts of organic bases with n-carbamyl-l-glutamic acid |
| US3846399A (en) * | 1969-04-10 | 1974-11-05 | Merck & Co Inc | Process for controlled stepwise synthesis of polypeptides |
| US3975342A (en) * | 1972-05-15 | 1976-08-17 | Biological Developments, Inc. | Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto |
| US3884898A (en) * | 1972-08-18 | 1975-05-20 | Syva Co | Normorphine derivatives bonded to proteins |
| US3843696A (en) * | 1972-09-05 | 1974-10-22 | Syva Co | Methadone analog compounds |
| US3878187A (en) * | 1972-09-11 | 1975-04-15 | Syva Co | Polypeptide derivatives of amphetamine and analogs for immunoassays |
| US3998799A (en) * | 1973-11-02 | 1976-12-21 | Interx Research Corporation | Novel, transient pro-drug forms of l-dopa |
| US4040907A (en) * | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
| US4025501A (en) * | 1975-03-20 | 1977-05-24 | Syva Company | Polypeptide propoxyphene derivatives for immunoassay reagents |
| US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
| DE3008265A1 (de) * | 1980-03-04 | 1981-09-17 | Siemens AG, 1000 Berlin und 8000 München | Verfahren zum sichtbarmachen von stationaeren waermeuebergangskoeffizientenfeldern auf photochemischem wege |
| US4399121A (en) * | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
| US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
| HU185535B (en) * | 1982-05-25 | 1985-02-28 | Mta Koezponti Hivatala | Process for preparing new gonadoliberin derivatives |
| US4457907A (en) * | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
| US4650675A (en) * | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
| ATE60340T1 (de) * | 1984-10-19 | 1991-02-15 | Battelle Memorial Institute | Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten. |
| GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| US4863735A (en) * | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| IN165717B (pt) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| DK406686D0 (da) * | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
| US5169933A (en) * | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5026827A (en) * | 1988-09-02 | 1991-06-25 | Matsushita Electric Industrial Co., Ltd. | Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine |
| US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| DE4006076C1 (pt) * | 1989-08-12 | 1990-12-13 | Fried. Krupp Gmbh, 4300 Essen, De | |
| US5767227A (en) * | 1989-11-03 | 1998-06-16 | Lotus Biochemical Corp. | Iodothyronine polymers |
| US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| EP0477931B1 (en) * | 1990-09-28 | 1994-08-17 | Mercian Corporation | Novel adriamycin derivatives |
| US5238714A (en) * | 1990-10-02 | 1993-08-24 | Board Of Regents, The University Of Texas System | Efficient microcapsule preparation and method of use |
| US5863899A (en) * | 1991-04-01 | 1999-01-26 | Cortech, Inc. | Bradykinin antagonists |
| US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| GB9215780D0 (en) * | 1992-07-24 | 1992-09-09 | Univ London Pharmacy | Peptide compounds |
| US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
| IL107400A0 (en) | 1992-11-10 | 1994-01-25 | Cortech Inc | Bradykinin antagonists |
| US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| AU5722694A (en) | 1993-11-05 | 1995-05-23 | Astra Aktiebolag | Novel amino acid derivatives |
| WO1995014033A1 (en) | 1993-11-19 | 1995-05-26 | Aktiebolaget Astra | Novel dipeptide derivatives |
| GB9401891D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
| US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
| US5910569A (en) * | 1994-11-22 | 1999-06-08 | Lotus Biochemical Corporation | Iodothyronine polymers |
| US5952499A (en) * | 1995-01-16 | 1999-09-14 | Commonwealth Scientific And Industrial Research Organisation | Therapeutic compound-fatty acid conjugates |
| US5846743A (en) * | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
| US5670477A (en) * | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| JP4256932B2 (ja) * | 1995-06-07 | 2009-04-22 | ジョエル ケイ． スワデッシュ | 抗原プロセシング細胞標的複合体 |
| US5762909A (en) * | 1995-08-31 | 1998-06-09 | General Electric Company | Tumor targeting with polymeric molecules having extended conformation |
| US5851536A (en) * | 1995-11-22 | 1998-12-22 | University Of Washington | Therapeutic delivery using compounds self-assembled into high axial ratio microstructures |
| CN1304058C (zh) * | 1996-03-12 | 2007-03-14 | Pg－Txl有限公司 | 水溶性紫杉醇产品 |
| GB9606975D0 (en) | 1996-04-02 | 1996-06-05 | Univ Birmingham | Anti-tumor agent |
| US6030941A (en) * | 1996-05-01 | 2000-02-29 | Avi Biopharma, Inc. | Polymer composition for delivering substances in living organisms |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5952294A (en) * | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| US6013633A (en) * | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| CN1263473A (zh) * | 1997-05-21 | 2000-08-16 | 利兰·斯坦福青年大学托管委员会 | 增加跨生物膜转运的组合物和方法 |
| TW460478B (en) * | 1997-08-15 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Phenethylamine derivatives |
| WO1999030727A1 (en) * | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| EP1053238B1 (en) * | 1998-01-29 | 2005-12-28 | Monash University | Therapeutic compounds |
| US6048736A (en) * | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| US6473669B2 (en) * | 1998-07-03 | 2002-10-29 | Kimberly-Clark Worldwide, Inc. | Controlling web tension, and accumulating lengths of web, by actively controlling velocity and acceleration of a festoon |
| US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| US7060708B2 (en) * | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| WO2003020200A2 (en) * | 2000-11-16 | 2003-03-13 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound and methods of making and using same |
| AU2002211863A1 (en) * | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| US20020151526A1 (en) * | 2000-10-06 | 2002-10-17 | Gallop Mark A. | Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism |
| US20020098999A1 (en) * | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Compounds for sustained release of orally delivered drugs |
| US6740641B2 (en) * | 2001-07-27 | 2004-05-25 | Euro-Celtique, S.A. | Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain |
| US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| US7375082B2 (en) * | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
| AU2003210454A1 (en) * | 2002-01-08 | 2003-07-24 | New River Pharmaceuticals, Inc. | Dendritic encapsulation of active agents |
| WO2003072735A2 (en) * | 2002-02-22 | 2003-09-04 | New River Pharmaceuticals Inc. | Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels |
| KR100822498B1 (ko) * | 2002-02-22 | 2008-04-16 | 샤이어 엘엘씨 | 규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물 |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| JP2006520392A (ja) * | 2003-03-13 | 2006-09-07 | コントロールド・ケミカルズ・インコーポレーテッド | 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法 |
| SI1644019T2 (en) * | 2003-05-29 | 2018-04-30 | Shire Llc | Abuse resistant amphetamine compounds |
| EA008864B1 (ru) | 2003-09-30 | 2007-08-31 | Нью Ривер Фармасьютикалз Инк. | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств |
| US7910947B2 (en) | 2006-07-04 | 2011-03-22 | Kyosemi Corporation | Panel-shaped semiconductor module |
-
2004
- 2004-09-30 EA EA200600696A patent/EA008864B1/ru unknown
- 2004-09-30 EP EP04789333A patent/EP1675555A4/en not_active Withdrawn
- 2004-09-30 WO PCT/US2004/032131 patent/WO2005032474A2/en not_active Ceased
- 2004-09-30 CA CA2540678A patent/CA2540678C/en not_active Expired - Fee Related
- 2004-09-30 US US10/953,119 patent/US7375083B2/en not_active Expired - Lifetime
- 2004-09-30 JP JP2006534093A patent/JP4691500B2/ja not_active Expired - Fee Related
- 2004-09-30 BR BRPI0414876-2A patent/BRPI0414876A/pt not_active IP Right Cessation
- 2004-09-30 MX MXPA06003619A patent/MXPA06003619A/es active IP Right Grant
- 2004-09-30 SG SG200808092-1A patent/SG147485A1/en unknown
- 2004-09-30 KR KR1020067008018A patent/KR100915284B1/ko not_active Expired - Fee Related
- 2004-09-30 AU AU2004277400A patent/AU2004277400B2/en not_active Ceased
- 2004-09-30 NZ NZ546226A patent/NZ546226A/en not_active IP Right Cessation
-
2006
- 2006-03-30 IL IL174683A patent/IL174683A0/en unknown
- 2006-04-28 NO NO20061925A patent/NO20061925L/no not_active Application Discontinuation
-
2009
- 2009-04-21 AU AU2009201552A patent/AU2009201552A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06003619A (es) | 2008-01-14 |
| US20050176646A1 (en) | 2005-08-11 |
| SG147485A1 (en) | 2008-11-28 |
| WO2005032474A3 (en) | 2006-09-21 |
| NZ546226A (en) | 2009-03-31 |
| EA008864B1 (ru) | 2007-08-31 |
| EP1675555A2 (en) | 2006-07-05 |
| AU2004277400B2 (en) | 2009-01-22 |
| KR100915284B1 (ko) | 2009-09-03 |
| JP4691500B2 (ja) | 2011-06-01 |
| IL174683A0 (en) | 2006-08-20 |
| AU2004277400A1 (en) | 2005-04-14 |
| EA200600696A1 (ru) | 2007-02-27 |
| BRPI0414876A (pt) | 2006-11-21 |
| EP1675555A4 (en) | 2011-03-09 |
| KR20060102556A (ko) | 2006-09-27 |
| CA2540678A1 (en) | 2005-04-14 |
| WO2005032474A2 (en) | 2005-04-14 |
| JP2007507520A (ja) | 2007-03-29 |
| US7375083B2 (en) | 2008-05-20 |
| CA2540678C (en) | 2011-02-22 |
| AU2009201552A1 (en) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061925L (no) | Farmasoytiske preparater for forebyggelse av overdose eller misbruk | |
| EA200700362A1 (ru) | Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью | |
| BRPI0417260A (pt) | derivados de azepinoindol como agentes farmacêuticos | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| NO20072352L (no) | Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet | |
| WO2008057802A3 (en) | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same | |
| BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| MY140576A (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
| WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| FR2878161B1 (fr) | Forme medicamenteuse orale, solide et concue pour eviter le mesusage | |
| UA92348C2 (en) | 17b-HSD1 AND STS INHIBITORS | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| TW200716618A (en) | Chemical compounds | |
| MX2007004765A (es) | Compuestos y metodos que modulan la actividad de la trombopoyetina. | |
| ATE553750T1 (de) | Feste orale mikropartikelförmige darreichungsform zum schutz vor missbrauch | |
| DK1359939T3 (da) | Sammensætning og fremgangsmåde til potensering af lægemidler | |
| WO2004087880A8 (en) | Compounds and their use to treat diabetes and related disorders | |
| BRPI0514269A (pt) | compostos heterocìclicos como agentes farmacêuticos | |
| DK1656131T3 (da) | Anvendelse af betain til behandling claudicatio intermittens | |
| TW200634002A (en) | Chemical compounds | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
| MY160963A (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
| SE0203817D0 (sv) | New composition | |
| WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |